Business
Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals
Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by sharehold
About this update from Rafael Holdings, Inc.
[{"type":"image","alt":"Rafael Holdings, Inc.","displaySize":"","headline":null,"caption":"Rafael Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":179,"height":61,"url":"https://media.zenfs.com/en/globenewswire.com/135483f9ca0ce750d79c23f2fecb7eff"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/czMSfXYLjlvGAI3Ot9zW5Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTIxMDtoPTcyO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/135483f9ca0ce750d79c23f2fecb7eff","width":179,"height":61}},"lazy":false},{"type":"text","content":"Cyclo Therapeutics’ TransportNPC™ Phase 3 clinical trial for Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, a rare and fatal genetic disease, is fully enrolled and results from the 48-week interim analysis are expected in the middle of 2025","length":261,"tagName":"p"},{"type":"text","content":"NEWARK, N.J. and GAINESVILLE, Fla., March 26, 2025 (GLOBE NEWSWIRE) -- Rafael Holdings, Inc. (NYSE: RFL), and Cyclo Therapeutics, Inc. (NASDAQ: CYTH) today announced the closing of their business combination following approval by shareholders of both companies. Rafael Holdings issued shares of its Class B common stock to Cyclo Therapeutics’ shareholders representing approximately 22% of the combined company, based on the exchange ratio in the merger agreement between the parties determined to be 0.3525. Rafael also issued warrants to purchase shares of Rafael Class B common stock to certain holders of Cyclo warrants. Rafael Holdings has identified Trappsol® Cyclo™ as its lead clinical asset and looks forward to the TransportNPC™ 48-week interim analysis. TransportNPC™ is a prospective, randomized, double-blind, placebo controlled, multi-center therapeutic study in Pediatric and Adult Patients with Niemann-Pick Disease Type C1.","length":940,"tagName":"p"},{"type":"text","content":"“The merger with Cyclo Therapeutics is a major step forward in our strategy to develop clinical stage assets in areas of high unmet medical need,” said Bill Conkling, President and CEO of Rafael Holdings. Bill added, “We are impressed with the execution of the team in fully enrolling a comprehensive clinical trial in NPC and we eagerly await the interim analysis in the middle of 2025. Rafael Holdings is excited to welcome the talented Cyclo Therapeutics’ team and we are committed to leveraging our resources to help brin...